Prediction of poor prognosis in breast cancer patients based on MicroRNA-21 expression: A meta-analysis

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Wang, Yanyan ^a   Zhang, Yujie ^a   Pan, Chi ^a   Ma, Feixia ^a   Zhang, Suzhan ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA 21; MICRORNA; MIRN21 MICRORNA, HUMAN;

ARTICLE; ASIAN; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; DISEASE FREE SURVIVAL; ETHNIC DIFFERENCE; GENE EXPRESSION; HUMAN; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; UPREGULATION; BREAST TUMOR; FEMALE; GENETICS; META ANALYSIS; PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; HUMANS; MICRORNAS; PROGNOSIS;

EID: 84923362449     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118647     Document Type: Article

References (58)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90. doi: 10.3322/caac.20107 PMID: 21296855
2. Siegel R, Ma JM, Zou ZH, Jemal A. Cancer Statistics, 2014. Ca-a Cancer Journal for Clinicians. 2014; 64: 9-29. doi: 10.3322/caac.21208 PMID: 24399786
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. 2010; 127: 2893-2917. doi: 10.1002/ijc.25516 PMID: 21351269
4. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clinical Chemistry. 2008; 54: E11-E79. doi: 10.1373/clinchem.2008.105601 PMID: 19042984
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297. PMID: 14744438
6. Ambros V. The functions of animal microRNAs. Nature. 2004; 431: 350-355. PMID: 15372042
7. Zhang BH, Pan XP, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Developmental Biology. 2007; 302: 1-12. PMID: 16989803
8. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99: 15524-15529. PMID: 12434020
9. Michael MZ, O'Connor SM, Pellekaan NGV, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Molecular Cancer Research. 2003; 1: 882-891. PMID: 14573789
10. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochemical and Biophysical Research Communications. 2005; 334: 1351-1358. PMID: 16039986
11. Zhong H, Xu L, Zhong JH, Xiao F, Liu Q, Huang HH, et al. Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma. Experimental and Therapeutic Medicine. 2012; 3: 763-770. PMID: 22969965
12. Wang J, Zhao JQ, Shi MJ, Ding Y, Sun HQ, Yuan FH, et al. Elevated Expression of miR-210 Predicts Poor Survival of Cancer Patients: A Systematic Review and Meta-Analysis. Plos One. 2014; 9: e89223. doi: 10.1371/journal.pone.0089223 PMID: 24586608
13. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103: 2257-2261. PMID: 16461460
14. Krichevsky AM, Gabriely G. MiR-21: a small multi-faceted RNA. Journal of Cellular and Molecular Medicine. 2009; 13: x-53.
15. Zhu SM, Si ML, Wu HL, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). Journal of Biological Chemistry. 2007; 282: 14328-14336. PMID: 17363372
16. Roy S, Yu Y, Padhye SB, Sarkar FH, Majumdar APN. Difluorinated-Curcumin (CDF) Restores PTEN Expression in Colon Cancer Cells by Down-Regulating miR-21. Plos One. 2013; 8: e68543. doi: 10.1371/journal.pone.0068543 PMID: 23894315
17. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. Journal of Biological Chemistry. 2008; 283: 1026-1033. PMID: 17991735
18. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama-Journal of the American Medical Association. 2008; 299: 425-436. doi: 10.1001/jama.299.4.425 PMID: 18230780
19. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival. Journal of Gastrointestinal Surgery. 2008; 12: 2171-2176. doi: 10.1007/s11605-008-0584-x PMID: 18642050
20. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clinical Chemistry. 2008; 54: 1696-1704. doi: 10.1373/clinchem.2007.101741 PMID: 18719201
21. Menendez P, Padilla D, Villarejo P, Palomino T, Nieto P, Menendez JM, et al. Prognostic Implications of Serum microRNA-21 in Colorectal Cancer. Journal of Surgical Oncology. 2013; 108: 369-373. doi: 10.1002/jso.23415 PMID: 23970420
22. Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Faverot F, et al. MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications. American Journal of Respiratory Cell and Molecular Biology. 2010; 42: 312-319. doi: 10.1165/rcmb.2009-0060OC PMID: 19502386
23. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Rna-a Publication of the Rna Society. 2008; 14: 2348-2360.
24. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 2011; 10: 507-517. PMID: 21270527
25. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine. 1998; 17: 2815-2834. PMID: 9921604
26. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine. 2002; 21: 3337-3351. PMID: 12407676
27. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16. PMID: 17555582
28. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology - A proposal for reporting. Jama-Journal of the American Medical Association. 2000; 283: 2008-2012.
29. Hamling J, Lee P, Weitkunat R, Ambuhl M. Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Statistics in Medicine. 2008; 27: 954-970. PMID: 17676579
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560. PMID: 12958120
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188. PMID: 3802833
32. Mantel N, Haenszel W. Statistical Aspects of the Analysis of Data from Retrospective Studies of Disease. Biometrics. 1959; 15: 639-640.
33. Cornfield J. A Method of Estimating Comparative Rates from Clinical Data - Applications to Cancer of the Lung, Breast, and Cervix. Journal of the National Cancer Institute. 1951; 11: 1269-1275. PMID: 14861651
34. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, et al. High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2(+) Inflammatory Breast Cancer. Plos One. 2014; 9: e83113. doi: 10.1371/journal.pone.0083113 PMID: 24416156
35. Ozgun A, Karagoz B, Bilgi O, Tuncel T, Baloglu H, Kandemir EG. MicroRNA-21 as an Indicator of Aggressive Phenotype in Breast Cancer. Onkologie. 2013; 36: 115-118. doi: 10.1159/000348678 PMID: 23485999
36. Yan LX, Huang MY, Wu QL, Shao JY. Abnormalities of miR-21 expression in human breast cancer is associated with distinctive pathologic features and shortened postoperative survival. Chinese Journal of Pathophysiology. 2009; 25: 676-681.
37. Qian BY, Katsaros D, Lu LG, Preti M, Durando A, Arisio R, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta 1. Breast Cancer Research and Treatment. 2009; 117: 131-140. doi: 10.1007/s10549-008-0219-7 PMID: 18932017
38. Sun B. The evaluation of curative effect of neoadjuvant chemotherapy in breast cancer patients and gene expression profiling for breast cancer prognosis. D.Ph. Thesis, The Academy of Military Medical Sciences, PLA China. 2009. Available: http://www.cnki.net/KCMS/detail/detail.aspx?QueryID=1&CurRec=1&recid=&filename=2009124589.nh&dbname=CDFD0911&dbcode=CDFD&pr=&urlid=&yx=&uid=WEEvREcwSlJHSldTTGJhYlRBMW5tM1phSGNCNW0rWk9ENXJkYVpTQ3YwdExHdkMrTE9zQzZKaTRTd1hFa2xBOUlkdz0=$9A4hF-YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!&v=MTE0NzhSOGVYMUx1eFlTN0RoMVQzcVRyV00xRnJDVVJMNmVadVZ2Rnl6aFU3ekFWMTI3RjdLNkd0VEVwcEViUEk=.
39. Lee JA, Lee HY, Lee ES, Kim I, Bae JW. Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast. Journal of Breast Cancer. 2011; 14: 269-275. doi: 10.4048/jbc.2011.14.4.269 PMID: 22323912
40. Ota D, Mimori K, Yokobori T, Iwatsuki M, Kataoka A, Masuda N, et al. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. International Journal of Oncology. 2011; 38: 955-962. doi: 10.3892/ijo.2011.926 PMID: 21271219
41. Walter BA, Gomez-Macias G, Valera VA, Sobel M, Merino MJ. miR-21 Expression in Pregnancy-Associated Breast Cancer: A Possible Marker of Poor Prognosis. Journal of Cancer. 2011; 2: 67-75. PMID: 21326627
42. Dong GZ, Liang XL, Wang DG, Gao HQ, Wang L, Wang LL, et al. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Medical Oncology. 2014; 31: 57. doi: 10.1007/s12032-014-0057-x PMID: 24930006
43. Markou A, Yousef GM, Stathopoulos E, Georgoulias V, Lianidou E. Prognostic Significance of Metastasis-Related MicroRNAs in Early Breast Cancer Patients with a Long Follow-up. Clinical Chemistry. 2014; 60: 197-205. doi: 10.1373/clinchem.2013.210542 PMID: 24132943
44. Muller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, et al. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Research and Treatment. 2014; 147: 61-68. doi: 10.1007/s10549-014-3079-3 PMID: 25086636
45. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IM, Zhang YQ, et al. MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer. Plos One. 2008; 3: E2436. doi: 10.1371/journal.pone.0002436 PMID: 18560586
46. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene. 2007; 26: 2799-2803. PMID: 17072344
47. Fu XN, Han YJ, Wu Y, Zhu XL, Lu X, Mao F, et al. Prognostic role of microRNA-21 in various carcinomas: a systematic review andmeta-analysis. European Journal of Clinical Investigation. 2011; 41: 1245-1253. doi: 10.1111/j.1365-2362.2011.02535.x PMID: 21521185
48. Zhou X, Wang XP, Huang ZB, Wang J, Zhu W, Shu YQ, et al. Prognostic Value of miR-21 in Various Cancers: An Updating Meta-Analysis. Plos One. 2014; 9: e102413. doi: 10.1371/journal.pone.0102413 PMID: 25019505
49. Zhu W, Xu B. MicroRNA-21 Identified as Predictor of Cancer Outcome: A Meta-Analysis. PloS one. 2014; 9: e103373. doi: 10.1371/journal.pone.0103373 PMID: 25098165
50. Xia XC, Yang BX, Zhai XG, Liu XY, Shen K, Wu ZJ, et al. Prognostic Role of microRNA-21 in Colorectal Cancer: a Meta-Analysis. Plos One. 2013; 8: e80426. doi: 10.1371/journal.pone.0080426 PMID: 24265822
51. Ma XL, Liu L, Liu XX, Li Y, Deng L, Xiao ZL, et al. Prognostic Role of MicroRNA-21 in Non-small Cell Lung Cancer: a Meta-analysis. Asian Pacific Journal of Cancer Prevention. 2012; 13: 2329-2334. PMID: 22901216
52. Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: Current and new predictors of metastasis. Journal of Mammary Gland Biology and Neoplasia. 2001; 6: 375-392. PMID: 12013528
53. Huang RS, Gamazon ER, Ziliak D, Wen YJ, Im HK, Zhang W, et al. Population differences in microRNA expression and biological implications. Rna Biology. 2011; 8: 692-701. doi: 10.4161/rna.8.4.16029 PMID: 21691150
54. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502. PMID: 16757721
55. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007; 72: 397-402. doi: 10.1159/000113489 PMID: 18196926
56. Duffy MJ. Predictive markers in breast and other cancers: A review. Clinical Chemistry. 2005; 51: 494-503. PMID: 15637130
57. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Science. 2010; 101: 2087-2092. doi: 10.1111/j.1349-7006.2010.01650.x PMID: 20624164
58. Liu R, Zhang CN, Hu ZB, Li G, Wang C, Yang CH, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. European Journal of Cancer. 2011; 47: 784-791. doi: 10.1016/j.ejca.2010.10.025 PMID: 21112772